Search markets
Search icon A magnifying glass. It indicates, "Click to perform a search".
Search markets
Search icon A magnifying glass. It indicates, "Click to perform a search".
Close icon Two crossed lines that form an 'X'. It indicates a way to close an interaction, or dismiss a notification.

Amgen Inc. Stock , AMGN

229.79 0.00 0.00%
Official Close 3/17/2023 NAS
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Friday 03/17/2023 the closing price of the Amgen Inc. share was $229.79 on NAS. Compared to the opening price on Friday 03/17/2023 on NAS of $233.57, this is a drop of 1.64%. Amgen Inc.'s market capitalization is $125.49 B by 533.98 M shares outstanding.
Is Amgen stock a Buy, Sell or Hold? Amgen stock has received a consensus rating of hold. The average rating score is Baa1 and is based on 24 buy ratings, 31 hold ratings, and 7 sell ratings.
What was the 52-week low for Amgen stock? The low in the last 52 weeks of Amgen stock was 223.30. According to the current price, Amgen is 102.91% away from the 52-week low.
What was the 52-week high for Amgen stock? The high in the last 52 weeks of Amgen stock was 296.63. According to the current price, Amgen is 77.47% away from the 52-week high.
What are analysts forecasts for Amgen stock? The 62 analysts offering price forecasts for Amgen have a median target of 250.08, with a high estimate of 310.00 and a low estimate of 182.00. The median estimate represents a 91.89 difference from the last price of 229.79.

Amgen Stock Snapshot

229.79
Bid
100.00
Bid Size
229.82
Ask
1,000.00
Ask Size
3/17/2023
Date
8:00 PM
Time
4.53 M
Volume
234.57
Prev. Close
233.57
Open
125.49 B
Market Cap
533.98 M
Number of Shares
228.52
Day Low
233.81
Day High
229.79
223.30
52 Week Low
296.63
52 Week High
229.79
8.46
Dividend
3.67
Dividend Yield
14.83
P/E Ratio
99.78
Free Float in %
17.95
EPS 2023
7.72
Book Value per Share
21.07
Cash Flow per Share

Amgen Historical Prices

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Amgen Analyst Data

Total Analysts: 62
Buy Ratings: 24 Neutral Ratings: 31 Sell Ratings: 7
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 182.00 Median: 250.08 Highest: 310.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Amgen Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
03/13/23 Wells Fargo & Co
Upgraded to Buy $265
02/02/23 SVB Leerink
Maintained Hold $267
02/01/23 Wells Fargo & Co
Maintained Hold $275
02/01/23 RBC Capital Markets
Maintained Hold $258
02/01/23 Oppenheimer & Co. Inc.
Maintained Buy $294
02/01/23 Cowen and Company, LLC
Maintained Buy $289
02/01/23 Credit Suisse
Maintained Sell $220
02/01/23 BMO Capital Markets
Maintained Buy $253
02/01/23 Barclays Capital
Maintained Sell $230
01/19/23 Piper Sandler
Maintained Buy $293
01/18/23 Barclays Capital
Maintained Sell $240
01/03/23 Wells Fargo & Co
Maintained Hold $285
12/22/22 SVB Leerink
Maintained Hold $282
12/13/22 Piper Sandler
Maintained Buy $299
12/06/22 Oppenheimer & Co. Inc.
Maintained Buy $310
11/18/22 Credit Suisse
Maintained Sell $240
11/04/22 RBC Capital Markets
Maintained Hold $240
11/04/22 Morgan Stanley
Maintained Buy $282
11/04/22 Piper Sandler
Maintained Buy $278
10/31/22 Barclays Capital
Downgraded to Sell $234
10/12/22 Barclays Capital
Maintained Hold $234
10/11/22 Morgan Stanley
Upgraded to Buy $279
08/09/22 Atlantic Equities
Maintained Sell $182
08/05/22 RBC Capital Markets
Maintained Hold $236
08/05/22 Piper Sandler
Maintained Buy $265
07/15/22 Morgan Stanley
Maintained Hold $253
06/01/22 Oppenheimer & Co. Inc.
Maintained Buy $290
05/23/22 SVB Leerink
Maintained Hold $256
05/10/22 Mizuho
Maintained Hold $208
04/28/22 RBC Capital Markets
Maintained Hold $223
04/28/22 BMO Capital Markets
Maintained Buy $243
04/28/22 Piper Sandler
Maintained Buy $260
04/12/22 Morgan Stanley
Maintained Hold $237
04/12/22 Barclays Capital
Maintained Hold $236
02/09/22 Morgan Stanley
Maintained Hold $238
02/09/22 Wells Fargo & Co
Maintained Hold $250
02/09/22 Barclays Capital
Maintained Hold $233
02/09/22 Oppenheimer & Co. Inc.
Maintained Buy $285
01/05/22 Bank of America Merrill Lynch
Downgraded to Hold $255
12/21/21 RBC Capital Markets
Maintained Hold $218
12/09/21 Wells Fargo & Co
Maintained Hold $210
12/06/21 Goldman Sachs
Maintained Buy $258
11/22/21 Mizuho
Maintained Hold $194
11/19/21 BMO Capital Markets
Maintained Buy $228
11/03/21 RBC Capital Markets
Maintained Hold $216
11/03/21 Barclays Capital
Maintained Hold $228
11/03/21 SVB Leerink
Maintained Hold $216
10/12/21 Morgan Stanley
Maintained Hold $235
09/23/21 Daiwa Securities
Downgraded to Hold $220
09/07/21 Morgan Stanley
Downgraded to Hold $251

Amgen Estimates* in USD

  2023 2024 2025 2026 2027
Revenue 27,845 29,788 30,110 31,285 30,923
Dividend 8.46 9.15 9.84 10.51 11.40
Dividend Yield (in %) 3.67 % 3.97 % 4.27 % 4.56 % 4.95 %
EPS 17.95 19.28 19.91 20.89 21.38
P/E Ratio 13.14 12.24 11.85 11.29 11.04
EBIT 13,497 14,375 14,377 15,169 15,078
EBITDA 16,129 16,086 15,584 17,893 20,477
Net Profit 9,662 10,376 10,691 11,122 11,052
Net Profit Adjusted 9,662 10,376 10,691 11,122 11,052
Pre-Tax Profit 11,666 12,603 12,864 13,661 12,505
Net Profit (Adjusted) 8,060 9,086 9,010 8,990 -
EPS (Non-GAAP) ex. SOE 18.95 22.25 23.99 - -
EPS (GAAP) 14.23 14.81 15.07 16.58 17.40
Gross Income - - - - -
Cash Flow from Investing -5,278 410 407 -1,072 -776
Cash Flow from Operations 9,509 11,766 10,768 11,569 11,459
Cash Flow from Financing 4,362 -7,841 -8,839 -9,483 -
Cash Flow per Share 21.07 22.46 16.01 - -
Free Cash Flow 9,889 11,615 9,763 13,547 12,808
Free Cash Flow per Share - - - - -
Book Value per Share 7.72 10.11 12.44 4.06 -
Net Debt 23,273 18,370 16,330 - -
Research & Development Exp. 4,660 5,029 5,081 5,198 5,180
Capital Expenditure 822 782 772 761 792
Selling, General & Admin. Exp. 5,584 6,078 6,121 6,280 6,128
Shareholder’s Equity 4,425 6,490 9,237 11,255 16,880
Total Assets 75,528 75,960 75,947 76,159 78,849
  Previous Quarter
ending 12/31/22 		Current Quarter
ending 03/31/23 		Next Quarter
ending 06/30/23 		Current Year
ending 12/31/23 		Next Year
ending 12/31/24
Earnings Estimates
No. of Analysts 21 19 19 22 21
Average Estimate 4.097 USD 4.001 USD 4.591 USD 17.954 USD 19.283 USD
Year Ago 4.360 USD 4.250 USD 4.650 USD 17.690 USD 17.954 USD
Publish Date 1/31/2023 4/25/2023 8/1/2023 - -
Revenue Estimates
No. of Analysts 20 18 17 21 20
Average Estimate 6,744 USD 6,232 USD 6,826 USD 27,845 USD 29,788 USD
Year Ago 6,846 USD 6,238 USD 6,594 USD 26,323 USD 27,845 USD
Publish Date 1/31/2023 4/25/2023 8/1/2023 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Amgen Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
Gordon Murdo 03/05/2023 7,947.00 55,621.00 n/a Buy No
Bradway Robert A 03/05/2023 27,915.00 648,712.00 n/a Buy No
Graham Jonathan P 03/05/2023 7,560.00 41,620.00 n/a Buy No
Khosla Rachna 03/05/2023 687.00 7,338.00 n/a Buy No
Santos Esteban 03/05/2023 7,753.00 65,676.00 n/a Buy No
Louie Linda H. 03/05/2023 387.00 9,679.00 n/a Buy No
REESE DAVID M 03/05/2023 7,947.00 56,167.00 n/a Buy No
Griffith Peter H. 03/05/2023 7,753.00 32,541.00 n/a Buy No
Grygiel Nancy A. 03/05/2023 968.00 14,032.00 n/a Buy No
Miller Derek 03/05/2023 920.00 6,905.00 n/a Buy No
Khosla Rachna 11/08/2022 387.00 6,630.00 292.90 Sell No
Grygiel Nancy A. 11/07/2022 545.00 13,009.00 293.54 Sell No
Drake Michael V 11/07/2022 171.00 810.00 n/a Buy No
Kullman Ellen Jamison 11/07/2022 222.31 10,112.98 n/a Buy No
ISHRAK OMAR 11/07/2022 222.31 2,301.91 n/a Buy No
Khosla Rachna 11/04/2022 168.00 7,017.00 269.04 Sell No
Louie Linda H. 11/04/2022 45.00 9,278.00 269.04 Sell No
Grygiel Nancy A. 11/04/2022 240.00 13,554.00 269.04 Sell No
Miller Derek 11/04/2022 63.00 5,973.00 269.04 Sell No
Louie Linda H. 11/01/2022 125.00 9,323.00 272.06 Sell No
REESE DAVID M 11/01/2022 2,440.00 48,136.00 272.06 Sell No
Griffith Peter H. 10/31/2022 3,030.00 24,675.00 270.35 Sell No
Graham Jonathan P 10/31/2022 1,644.00 33,963.00 270.35 Sell No
Williams R Sanders 08/21/2022 200.00 5,301.00 249.96 Sell No
Gordon Murdo 08/21/2022 400.00 47,484.00 n/a Sell No

Amgen Dividend Calendar

Date Name Dividend *yield Currency
2022 Amgen Inc. 7.76 2.95 USD
2021 Amgen Inc. 7.04 3.13 USD
2020 Amgen Inc. 6.40 2.78 USD
2019 Amgen Inc. 5.80 2.41 USD
2018 Amgen Inc. 5.28 2.71 USD
2017 Amgen Inc. 4.60 2.65 USD
2016 Amgen Inc. 4.00 2.74 USD
2015 Amgen Inc. 3.16 1.95 USD
2014 Amgen Inc. 2.44 1.53 USD
2013 Amgen Inc. 1.88 1.65 USD
2012 Amgen Inc. 1.44 1.67 USD
2011 Amgen Inc. 0.56 0.87 USD
2010 Amgen Inc. - - USD
2009 Amgen Inc. - - USD
2008 Amgen Inc. - - USD
2007 Amgen Inc. - - USD
2006 Amgen Inc. - - USD
2005 Amgen Inc. - - USD
2004 Amgen Inc. - - USD
2003 Amgen Inc. - - USD
2002 Amgen Inc. - - USD
2001 Amgen Inc. - - USD
2000 Amgen Inc. - - USD
1999 Amgen Inc. - - USD
*Yield of the Respective Date

Amgen Inc. Calendar

Event Estimate Info Date
Earnings Report 4.001 USD Q1 2023 Earnings Release 04/25/2023
Earnings Report 4.591 USD Q2 2023 Earnings Release 08/01/2023
Earnings Report - Q3 2023 Earnings Release 10/31/2023
Earnings Report - Q4 2023 Earnings Release 01/30/2024

Amgen Inc. Past Events

Event Actual EPS Info Date
Earnings Report 4.090 USD Q4 2022 Earnings Release 01/31/2023
Press Conference - - 08/04/2022
Shareholders' Meeting - - 05/17/2022

Amgen Profile

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr. , Franklin Pitcher Johnson, Jr. , George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
4
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Amgen Shareholder

Owner in %
Freefloat 99.78
Vanguard Group, Inc. (Subfiler) 8.57
State Street Corp. 5.56
Capital Research & Management Co. (Global Investors) 4.15
BlackRock Fund Advisors 3.48
Vanguard Total Stock Market Index Fund 3.08
PRIMECAP Management Co. 2.86
Vanguard 500 Index Fund 2.32
BlackRock Institutional Trust Co. NA 2.26
Capital Research & Management Co. (Global Investors) 2.23
Geode Capital Management LLC 2.13
Charles Schwab Investment Management, Inc. 1.74
Vanguard PRIMECAP Fund 1.71
Morgan Stanley Smith Barney LLC 1.54
Invesco QQQ Trust 1.30
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.

Amgen Management

Name Job
Robert A. Bradway Chairman, President & Chief Executive Officer
Linda H. Louie Chief Accounting Officer & Vice President-Finance
Nancy A. Grygiel Chief Compliance Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
Derek Miller Chief Human Resources Officer
Mike Zahigian Chief Information Officer & Senior Vice President
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Omar S. Ishrak Director
Murdo J. Gordon EVP-Global Commercial Operations
Lori A. Johnston Executive Vice President
Esteban Santos Executive Vice President-Operations
David M. Reese Executive Vice President-Research & Development
Tyler E. Jacks Independent Director
Brian J. Druker Independent Director
Amy E. Miles Independent Director
Greg C. Garland Independent Director
Ellen Jamison Kullman Independent Director
Charles M. Holley Independent Director
Michael V. Drake Independent Director
Wanda M. Austin Independent Director
Ronald D. Sugar Independent Director
Robert Sanders Williams Independent Director
Robert A. Eckert Lead Independent Director
Robert T. Fremeau Scientific Director
Jonathan P. Graham Secretary, Executive VP & General Counsel
Susan Sweeney Senior VP-Global Marketing, Access & Capabilities
Mark J. Taisey Senior VP-Global Regulatory Affairs & Strategy
David A. Piacquad Senior Vice President
Rachna Khosla Senior Vice President-Business Development
Judy L. Brown Senior Vice President-Corporate Affairs
Victoria H. Blatter Senior Vice President-Global Government Affairs
Arvind K. Sood Vice President-Investor Relations